A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2017
At a glance
- Drugs KO 947 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Kura Oncology
- 15 May 2017 According to a Kura Oncology media release, data from this trial are expected in 2018.
- 07 Apr 2017 According to a Kura Oncology media release, company has identified two tumor-specific cohorts, non-small cell lung cancer with mutations in RAS or BRAF and squamous cell carcinomas as potential extension cohortsin this trial.
- 07 Apr 2017 According to a Kura Oncology media release, the first patient has been dosed in this trial.